Expertise in
1
conditions

Dr. Ramey D. Littell

Obstetrics and Gynecology
Kaiser Permanente
San Francisco Medical Center
2238 Geary Blvd, 2nd Floor, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
1
conditions
Kaiser Permanente
San Francisco Medical Center
2238 Geary Blvd, 2nd Floor, 
San Francisco, CA 

Overview

Ramey Littell is an Obstetrics and Gynecologist practicing medicine in San Francisco, California.

Dr. Littell is highly rated in 1 condition, according to our data. His clinical expertise encompasses Ovarian Cancer, Vaginal Cancer, Endometrial Cancer, Oophorectomy, and Hysterectomy.

He is actively involved in clinical research, co-authoring 32 peer reviewed articles and participating in 10 clinical trials. Dr. Littell is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

San Francisco Medical Center
2238 Geary Blvd, 2nd Floor, San Francisco, CA 94115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: August 07, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

32 Total Publications

Innovations in Surgical Communication 5-When Surgery Is a Bad Idea, Focus on the Goals.
Innovations in Surgical Communication 5-When Surgery Is a Bad Idea, Focus on the Goals.
Journal: JAMA surgery
Published: May 07, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Lee-may A. Chen
Obstetrics and Gynecology
Expertise in
18
conditions
Dr. Lee-may A. Chen
Obstetrics and Gynecology
Referral may be required

Gynecologic Oncology Center

1825 4th St Fl 6, 
San Francisco, CA 
 (1.6 miles away)
415-353-9600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lee-may Chen is an Obstetrics and Gynecologist practicing medicine in San Francisco, California. Dr. Chen is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Salpingo-Oophorectomy, and Oophorectomy.

Expertise in
22
conditions
Dr. John C. Chan
Oncology | Obstetrics and Gynecology
Expertise in
22
conditions
Dr. John C. Chan
Oncology | Obstetrics and Gynecology
Referral may be required
Before you request

John C.K. Chan, MD Private Practice

1100 Van Ness Ave, 4th Fl, 
San Francisco, CA 
 (1.1 miles away)
415-600-0930
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Chan is an Oncologist and an Obstetrics and Gynecologist practicing medicine in San Francisco, California. Dr. Chan is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Oophorectomy, and Hysterectomy. Dr. Chan is board certified in Obstetrics And Gynecology - Board Certified , OB & Gyn (Sub: Gynecologic Oncology), Gynecologic Oncology - Board Certified, and Obstetrics & Gynecology. Dr. Chan is currently accepting new patients.

Expertise in
12
conditions
Dr. Jocelyn S. Chapman
Obstetrics and Gynecology
Expertise in
12
conditions
Dr. Jocelyn S. Chapman
Obstetrics and Gynecology
Referral may be required

Gynecologic Oncology Center

1825 4th St Fl 6, 
San Francisco, CA 
 (1.6 miles away)
415-353-9600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jocelyn Chapman is an Obstetrics and Gynecologist practicing medicine in San Francisco, California. Dr. Chapman is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Testicular Yolk Sac Tumor, Hysterectomy, and Oophorectomy.

Frequently Asked Questions about Dr. Ramey D. Littell

How do I make an appointment with Dr. Ramey D. Littell?

You can book an appointment with Dr. Ramey D. Littell by calling their office at 415-833-4199. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ramey D. Littell a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ramey D. Littell is classified as an Advanced expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ramey D. Littell specialize in?

While Dr. Ramey D. Littell is a Obstetrics and Gynecology, they have specific expertise in Ovarian Cancer, Vaginal Cancer, and Oophorectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Ramey D. Littell participate in research or clinical trials?

Yes. Dr. Ramey D. Littell has published 32 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Ramey D. Littell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Littell's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile